Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index (COMETI P2)
Utilizing CellSearch® technology, the ability to both enumerate and reliably and reproducibly characterize circulating tumor cells (CTC) for tumor markers that predict endocrine sensitivity (estrogen receptor [ER] and Bcl-2) and resistance (HER2 and Ki67) has been demonstrated. An algorithm for a CTC-Endocrine Therapy Index (CTC-ETI) has been constructed that can be calculated for each patient using the CTC enumeration and marker results. The primary goal of this study is to determine a CTC-ETI in ER positive, HER2 negative metastatic breast cancer patients before the initiation of a new endocrine therapy for the identification of patients that will progress rapidly.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index|
- Rapid Disease Progression [ Time Frame: Within 3 months after initiation of a new line of enrocrine therapy ] [ Designated as safety issue: No ]Within 30 days prior to the initiation of therapy, chest & abdomen body imaging (computed tomography [CT], or magnetic resonance imaging [MRI] scanning) plus bone scintigraphic imaging (bone scans or PET scans) or PET-CT scans which encompass both will be performed to identify target and non-target lesions that will be followed with the same imaging techniques 3 months after the initiation of therapy. Objective tumor response will be determined using RECIST v1.1 criteria. Rapid disease progression will be defined as disease progression according to RECIST v1.1 criteria or death due to metastatic breast cancer within 3 months of starting a new ET.
- Progression Free Survival (PFS) [ Time Frame: Up to 12 months after initiation of therapy ] [ Designated as safety issue: No ]Within 30 days prior to the initiation of of a new line of endocrine therapy (ET), chest & abdomen body imaging (computed tomography [CT], or magnetic resonance imagine [MRI] scanning) plus bone scintigraphic imaging (bone scans or PET scans) or PET-CT scans which encompass both will be performed to identify target and non-target lesions that will be followed with the same imaging techniques 3 months, 6 months, 9 months, and up to 12 months after the initiation of therapy. Objective tumor response will be determined using RECIST v1.1 criteria. Progression Free Survival (PFS) will be measured as the time from the date of starting ET until the date of first documentation of progressive disease according to RECIST v1.1 criteria or death due to any cause. In the absence of these events, PFS will be censored at the date of the last objective disease assessment (up to a maximum of 12 months after the initiation of ET).
- Biomarker correlations [ Time Frame: End of study (up to 12 months after enrollment of final patient) ] [ Designated as safety issue: No ]Correlate the status of the biomarkers on baseline circulating tumor cells (CTC) with the status of the same biomarkers in primary and/or metastatic tissue collected from the patients.
- Analytic Validity [ Time Frame: Baseline blood draw (within 30 days prior to the initiation of therapy) ] [ Designated as safety issue: No ]
Demonstrate that the circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) can be accurately determined at initiation of a new endocrine therapy (baseline) in patients with ER positive, HER2 negative metastatic breast cancer in multiple centers across North America. Baseline blood sample will be evaluated for the following:
- successful calculation of CTC-ETI;
- successful enumeration of CTC in the four aliquots;
- successful determination of CTC Bio-Score for all 4 markers when the average number of cells is ≥5 CTC/7.5mL of blood.
Biospecimen Retention: Samples With DNA
Cartridges containing Circulating Tumor Cells (isolated by CellSearch) as well as primary and/or metastatic tumor tissue (blocks or slides).
|Study Start Date:||April 2013|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Female patients 18 years or older with estrogen receptor (ER) positive, HER2 negative, progressive metastatic breast cancer after one or more lines of endocrine therapy (ET) who are initiating a new ET will be enrolled into the study. Patients must have immunohistochemistry (IHC) proven ER positive disease, IHC and/or fluorescence in-situ hybridization (FISH) proven HER2 negative disease, and an ECOG performance status of 0-2. Patients with brain metastases only or those who are progressing on fulvestrant are not eligible for the study.
Other: Blood collection
Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
Patients with estrogen receptor (ER) positive metastatic breast cancer (MBC) starting their first line of endocrine therapy (ET) only have a 30-50% chance of receiving clinical benefit. For the other 50-70% of patients, ET is ineffective and these patients should probably be treated with chemotherapy, as is done for ER negative patients. More importantly, in nearly every clinical trial of ET in ER positive, MBC patients, between 15-30% of enrolled patients progress in the first 2-3 months, regardless of whether they are receiving first or later lines of ET. Currently there is no validated method to identify which ER positive MBC patients will be refractory to ET. Therefore, almost all ER positive patients are treated with serial endocrine therapies before switching to chemotherapy. The investigators propose that a subset of these patients would be better served with chemotherapy, in spite of its increased toxicity profile, rather than delaying chemotherapy during a several month trial of ineffective, albeit less toxic, ET.
To try and predict benefit from or resistance to ET, an index (the CTC-ETI) has been created that takes into account the number of CTC (which is prognostic) as well as the phenotype of the CTC, based on the hypothesis that relative levels of ER and Bcl-2 (high=benefit) and HER2 and Ki67 (high=resistance) are predictive of ET responsiveness or resistance. Although the preliminary data demonstrate the ability to detect, enumerate, and characterize CTC utilizing the CellSearch® System, the purpose of the current study is to establish proof of principle that these 4 markers can be used to generate a CTC-ETI which can be performed at baseline from patients enrolled at different centers, and that baseline CTC-ETI predicts relative outcome for patients with ER positive MBC starting a new ET, and can be monitored in such patients during ET. Successful completion of this study will set the stage for a larger, definitive study designed to demonstrate the clinical utility of a "refined" CTC-ETI in patients with ER positive, HER2 negative MBC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01701050
|Contact: Scott Adams, MSfirstname.lastname@example.org|
|Contact: Robert McCormack, PhDemail@example.com|
|United States, Florida|
|Florida Cancer Specialists||Recruiting|
|Ft. Myers, Florida, United States, 33905|
|Contact: Lowell L Hart, MD 239-938-0800 firstname.lastname@example.org|
|Principal Investigator: Lowell L Hart, MD|
|Florida Cancer Specialists||Recruiting|
|St. Petersburg, Florida, United States, 33705|
|Contact: Gail Wright, MD 727-216-1143 email@example.com|
|Principal Investigator: Gail Wright, MD|
|H. Lee Moffitt Cancer Center and Research Institute, Inc.||Recruiting|
|Tampa, Florida, United States, 33612|
|Contact: Hatem Soliman, M.D. 813-745-4933 firstname.lastname@example.org|
|Principal Investigator: Hatem Soliman, M.D.|
|United States, Massachusetts|
|Dana-Faber Cancer Institute||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Ian Krop, M.D., Ph.D. 617-632-3427 Ian_Krop@dfci.harvard.edu|
|Principal Investigator: Ian Krop, M.D., Ph.D.|
|United States, Michigan|
|University of Michigan Comprehensive Cancer Center||Recruiting|
|Ann Arbor, Michigan, United States, 48109|
|Contact: Daniel F Hayes, M.D. 734-615-6725 email@example.com|
|Contact: Costanza Paoletti, M.D. 734-647-7250 firstname.lastname@example.org|
|Principal Investigator: Daniel F Hayes, M.D.|
|Sub-Investigator: Costanza Paoletti, M.D.|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Minetta Liu, MD 507-293-1732 email@example.com|
|Principal Investigator: Minetta Liu, MD|
|United States, North Carolina|
|Durham, North Carolina, United States, 27710|
|Contact: Kelly Marcom, M.D. 919-684-3877 firstname.lastname@example.org|
|Principal Investigator: Kelly Marcom, M.D.|
|United States, Pennsylvania|
|Abramson Cancer Center, University of Pennsylvania||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Angela DeMichele, M.D. 215-614-1850 Angela.DeMichele@uphs.upenn.edu|
|Principal Investigator: Angela DeMichele, M.D.|
|Thomas Jefferson University||Recruiting|
|Philadelphia, Pennsylvania, United States, 19107|
|Contact: Massimo Cristofanilli, MD 713-705-2122 email@example.com|
|Principal Investigator: Massimo Cristofanilli, MD|
|United States, Tennessee|
|Tennessee Oncology, PLLC||Recruiting|
|Nashville, Tennessee, United States, 37203|
|Contact: Denise A Yardley, MD 615-329-7274 firstname.lastname@example.org|
|Principal Investigator: Denise A Yardley, MD|
|Mt. Sinai Hosp., Marvette Koffler Breast Center||Recruiting|
|Toronto, Ontario, Canada, M5G 1X5|
|Contact: Pamela Goodwin, M.D. 416-586-8605 email@example.com|
|Principal Investigator: Pamela Goodwin, M.D.|
|Princess Margaret Hospital||Recruiting|
|Toronto, Ontario, Canada, M5G 2M9|
|Contact: Eitan Amir, MD, PhD 416-946-4501 ext 5181 firstname.lastname@example.org|
|Principal Investigator: Eitan Amir, MD, PhD|
|Principal Investigator:||Daniel F Hayes, M.D.||University of Michigan Cancer Center|
|Principal Investigator:||Costanza Paoletti, M.D.||University of Michigan Cancer Center|